Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 98

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Hormone receptor positive breast cancer+1

Recruiting

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Study on Advanced Laryngeal and Hypopharyngeal Cancer: Comparing Docetaxel, Cisplatin, and Pembrolizumab for Patients Eligible for Laryngectomy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide

Plasma cell myeloma

Recruiting

Study on Elranatamab for Patients with Multiple Myeloma Continuing from Previous Clinical Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab

Aortic valve stenosis

Recruiting

Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol

Acute lymphocytic leukaemia recurrent+5

Recruiting

Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mb-Cart20.1

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axicabtagene Ciloleucel

Neovascular age-related macular degeneration

Recruiting

Study on Vitrectomy, Alteplase, and Aflibercept for Patients with Wet Age-Related Macular Degeneration and Submacular Hemorrhage

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant

Juvenile idiopathic arthritis

Recruiting

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tocilizumab

Aortic valve replacement

Recruiting

Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.